$COAG

Biotech stocks hit 52-week highs on July 20, 2026, attributed to upcoming clinical catalysts. Xencor (XNCR) reached $20.26, up 7%, with Phase 2b XENITH-UC interim results expected by year-end 2026. Hemab (COAG) hit $52.15 after positive Phase 2 Sutacimig data. Monopar (MNPR) hit $115 on Phase 3 ALXN1840 Wilson disease results. SOPHiA (SOPH) rose above $6.50; Q1 revenue was $21.7M and 2026 guidance is $92M to $94M.

Investing.com reports Friday’s market weakness, with Nasdaq down about 1% and stocks set for a weekly loss. It lists major movers including Micron Tech (MU) up 3.66%, Oracle (ORCL) up 2.7%, and Coca-Cola (KO) down 4.66% after fairlife suspends US production following a cyberattack. Other cited moves include Applied Materials (AMAT) down 4.3% and SpaceX (SPCX) down 4.07%.

Hemab Therapeutics (COAG) presented Phase 2 long-term extension data for Sutacimig at ISTH 2026, treating 34 patients with median 6.9 months exposure up to 15.9 months. The company reported an ATBR 92% reduction, manageable safety, and FDA alignment to move to Phase 3 with a weekly regimen. Wedbush reiterated Outperform and a $55 target.

Hemab Therapeutics (Nasdaq:COAG) reported Phase 2 long-term extension data for sutacimig in Glanzmann thrombasthenia and preclinical results in Factor VII deficiency at ISTH 2026. In 34 patients (median 6.9 months, up to 15.9), treated bleed rates fell, with no Grade 3+ related AEs. FDA endorsed a 0.2 mg/kg Q1 week Phase 3 plan in 2H 2026.

Biotech stocks hit 52-week highs on July 14, 2026. Hemab Therapeutics (COAG) reached $42.03 after positive Phase 2 results for HMB-002 and launched HMB-003. Alamar Biosciences (ALMR) hit $29.43 on a U.S. university proteomics partnership. Progyny (PGNY) rose 4% to $32; 2026 revenue guidance $1.365B-$1.405B. 10x Genomics (TXG) closed $43.98; 2026 revenue $600M-$625M. Viemed (VMD) peaked $12.61; 2026 net revenue $312M-$320M.

Hemab Therapeutics (NASDAQ:COAG) reported early clinical and pharmacology findings for HMB-002 in von Willebrand disease, saying a single 150 mg subcutaneous dose increased VWF and FVIII by at least 2.4-fold, supported thrombin generation, and showed mild to moderate adverse events. The company also introduced HMB-003 for heavy menstrual bleeding. COAG shares were up 6.42% to $40.47.

Hemab Therapeutics (Nasdaq:COAG) reported new HMB-002 clinical data for von Willebrand disease at ISTH 2026, citing dose-dependent increases of VWF and FVIII, including ≥2.4-fold peaks in cohort A3 (150 mg), plus normalization of thrombin generation and APTT. It also announced HMB-003, a non-hormonal plasmin inhibitor targeting heavy menstrual bleeding.

RA CAPITAL MANAGEMENT, L.P. purchased 67,669 indirectly-held shares of Hemab Therapeutics Holdings, Inc. (COAG) at an average of $24.97 ($24.89–$24.98, $1.69M total) across 2 trades over 2026-06-15 to 2026-06-16.